Formulation and in vitro evaluation of alfuzosin extended release tablets using directly compressible eudragit

Indian Journal of Pharmaceutical Sciences

Volumn 71, Issue 3, 2009, Pages 252-258

  Roni, M A ^a   Kibria, G ^a   Jalil, R ^a  

^a UNIVERSITY OF DHAKA   (Bangladesh)

Author keywords

Alfuzosin hydrochloride; Eudragit RS PO; Hydroxypropylmethylcellulose; Matrix tablet; Release kinetics

Indexed keywords

ALFUZOSIN; EUDRAGIT; HYDROXYPROPYLMETHYLCELLULOSE; MAGNESIUM STEARATE; METHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; POLYMER;

ARTICLE; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FACTORIAL DESIGN; IN VITRO STUDY; KINETICS; MATHEMATICAL MODEL; QUANTITATIVE ANALYSIS; SUSTAINED DRUG RELEASE; TABLET FORMULATION;

EID: 70349814634     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.56019     Document Type: Article

References (30)

1. Guay DR. Extended-release alfuzosin hydrochloride: A new alphaadrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother 2004;2:14-23.
2. Beduschi MC, Beduschi R, Oesterling JE. Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective a 1A-adrenergic antagonist. Urology 1998;51:861-872
3. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant a1-adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995;288:201-207
4. Clayton LT, editor. Taber's Cyclopedic medical dictionary. 18th ed. New Delhi: Jaypee Brothers; 1998. p. 212.
5. British Pharmacopoeia, Vol.I, London: Her Majesty's Stationary Office, British Pharmacopoeia Commission; 2005. p. 73.
6. Liu Q, Fassihi R. Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. Int J Pharm 2008;348:27-34.
7. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12-18 month assessment; BPHALF Group. Br J Urol 1993;72:615-620
8. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 24-30 month survey, BPHALF group. Br J Urol 1994;74:579-584
9. Lukacs B, Grange JC, McCarthy C, Comet D. Clinical uroselectivity: A 3-year follow-up in general practice: BPA Group in General Practice. Eur Urol 1998;33:28-33.
10. Debruyne FMJ, Jardin A, Colloi D. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998;34:169-175
11. Kerrebroeck VP, Jardin A, Laval KU, Cangh VP. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000;37:306-313
12. Viswanathan NB, Ramakrishnan S, Raghuvanshi RS, Rampal A. Sustained release compositions containing Alfuzosin. US Patent 2003;20060147530.
13. Nair A, Gupta R, Vasanti S. In vitro controlled release of Alfuzosin hydrochloride using HPMC-based matrix tablets and its comparison with marketed product. Pharm Dev Tech 2007;12:621-625
14. Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eu J Pharm Biopharm 2001;52:75-82.
15. Al-Taani BM, Tashtoush BM. Effect of Microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium. AAPS PharmSciTech 2003;4:43.
16. Gohel MC, Patel TP, Bariya SH. Studies in preparation and evaluation of pH-independent sustained-release matrix tablets of verapamil HCl using directly compressible eudragits. Pharm Dev Tech 2003;8:323-333
17. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev 1993;11:37-57. (Pubitemid 23257482)
18. Vyas SP, Jain NK, Khana S. Formulation and performance evaluation of controlled-release diclofenac sodium tablets. J Control Release 1989;10:219-223
19. Silvina AB, Maria CL, Claudio JS. In vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Pharmaceut Sci 2002;5:213-219
20. Aulton ME, editor. Pharmaceutics, the science of dosage form design. Oxford: Churchill Livingstone; 2005. p. 133-134
21. Dissolution methods for drug products, US FDA. Available at: http:// www.accessdata.fda.gov/scripts/cder/dissolution/dsp-SearchResults-Dissolutions. cfm?PrintAll=1. Accessed March 12, 2008.
22. Ritger PL, Peppas NS. A simple equation for description of solute release II: Fickian and anomalous release from swellable devices. J Control Release 1987;5:37-42.
23. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
24. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001;48:139-157
25. Möckel J, Lippold BC. Zero-order drug release from hydrocolloid matrices. Pharm Res 1993;10:1066-1070
26. United States Food and Drug Administration. Guidance for industry, dissolution testing of immediate release solid oral dosage forms; 1997.
27. Mitchell K, Ford JL, Armstrong DJ, Elliott PN, Hogan JE, Rostron C. The influence of drugs on the properties of gels and swelling characteristics of matrices containing methylcellulose or hydroxypropylmethycellulose. Int J Pharm 1993;100:165-173
28. Katzhendler I, Hoffman A, Goldbergern A, Friedman M. Modeling of drug release from erodible tablets. J Pharm Sci 1997;86:110-115 (Pubitemid 127489667)
29. Gao P, Nixon P, Skoug J. Diffusion in HPMC gels: II: Prediction of drug release rates from hydrophilic matrix extended-release dosage forms. Pharm Res 1995;12:965-971
30. Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC. Optimization of sustained release propranolol dosage form using factorial design and response surface methodology. Biol Pharm Bull 2004;27:1626-1629